Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

This study evaluated the preclinical activity and molecular predictors of response to gefitinib (Iressa®, Astra Zeneca Inc, UK) in nasopharyngeal carcinoma (NPC). The activity of gefitinib was evaluated in four human NPC cell lines—HK1, HONE-1, CNE2, C666-1. A representative gefitinib-sensitive (HK1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Brigette B.Y., Lui, Vivian W.Y., Poon, Fan Fong, Wong, S.C. Cesar, To, Ka Fai, Wong, Elaine, Chen, Honglin, Lo, Kwok Wai, Tao, Qian, Chan, Anthony T.C.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2009
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953619/
https://www.ncbi.nlm.nih.gov/pubmed/19756373
http://dx.doi.org/10.1007/s10637-009-9316-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953619/
https://www.ncbi.nlm.nih.gov/pubmed/19756373
http://dx.doi.org/10.1007/s10637-009-9316-7

Ejemplares similares